28 unchanged sentences
The information required by this item is incorporated by reference to the information in our Proxy Statement in the sections titled “Independent Registered Public Accounting Firm Fees and Services” and “Pre-Approval Policies and Procedures.”
−Removed: Exhibits, Financial Statement Schedules.
+Added: Exhibits and Financial Statement Schedules.
Exhibit Index
7 unchanged sentences
Amended and Restated Investors’ Rights Agreement, by and among the Company and the investors listed therein, dated as of February 13, 2019
−Removed: Form of Indemnification Agreement for directors and officers
+Added: Form of Indemnification and Advancement Agreement for directors and officers
2018 Equity Incentive Plan, as amended
2 unchanged sentences
Fourth Amendment to 2018 Equity Incentive Plan, dated as of December 8, 2021
−Removed: Form of Stock Option Agreement under 2018 Equity Incentive Plan
+Added: Form of Stock Option Grant Notice and Stock Option Agreement under 2018 Equity Incentive Plan
2021 Incentive Award Plan
5 unchanged sentences
2021 Employee Stock Purchase Plan
+Added: Amendment No.
+Added: 1 to the 2021 Employee Stock Purchase Plan, dated as of October 27, 2022
Offer Letter and Employment Agreement by and between the Company and Steven D.
Harr, M.D., dated as of September 27, 2018
−Removed: Offer Letter and Employment Agreement by and between the Company and Richard Mulligan, Ph.D., dated as of April 23, 2020
−Removed: Offer Letter and Employment Agreement by and between the Company and Christian Hordo, dated as of November 10, 2018
Incorporated by Reference
Exhibit Description
+Added: Offer Letter and Employment Agreement by and between the Company and Richard Mulligan, Ph.D., dated as of April 23, 2020
+Added: Offer Letter and Employment Agreement by and between the Company and Christian Hordo, dated as of November 10, 2018
Offer Letter and Employment Agreement by and between the Company and Nathan Hardy, dated as of October 8, 2018
−Removed: Offer Letter and Employment Agreement by and between the Company and James J.
−Removed: MacDonald, dated as of October 2, 2018
+Added: Offer Letter by and between the Company and Bernard Cassidy, dated as of September 8, 2022
Non-Employee Director Compensation Program
5 unchanged sentences
Amendment No.
−Removed: 1 to Patents Sub-License Agreement by and between Pulsalys and Cobalt, dated as of May 26, 2020
+Added: 1 to Patents Sub-License Agreement by and between the Company, Pulsalys and Cobalt, dated as of May 26, 2020
+Added: Amendment No.
+Added: 2 to Patents Sub-License Agreement by and between the Company and Pulsalys, dated as of March 9, 2022
Exclusive License Agreement by and between the Company and The Regents of the University of California (The Regents) acting through The Technology Development Group of the University of California, Los Angeles (UCLA), dated as of March 22, 2019
4 unchanged sentences
Fourth Amendment to License Agreement by and between the Company and Harvard, dated as of October 25, 2021
+Added: Fifth Amendment to License Agreement by and between the Company and Harvard, dated as of February 9, 2023
+Added: Incorporated by Reference
+Added: Exhibit Description
Exclusive License Agreement by and between the Company and The Regents, acting through its Office of Technology Management, University of California San Francisco (UCSF), dated as of January 2, 2019
4 unchanged sentences
Amended and Restated Exclusive Patent License Agreement by and among the Company, Oscine Corp., and University of Rochester, dated as of September 10, 2020
−Removed: Seed Bank Supply Agreement by and between Oscine Therapeutics (U.S.) Inc.
−Removed: and Hadasit Medical Research Services and Development Ltd.
−Removed: (Hadasit), dated as of July 9, 2018
−Removed: Incorporated by Reference
−Removed: Exhibit Description
+Added: Offer Letter and Employment Agreement by and between the Company and Sunil Agarwal, M.D., dated as of May 20, 2019
+Added: Non-Exclusive License and Development Agreement by and between the Company and Fujifilm Cellular Dynamics, Inc.
+Added: (FCDI), dated as of February 1, 2021
Amendment No.
−Removed: 1 to Seed Bank Supply Agreement by and among the Company, Oscine Corp., and Hadasit, dated as of September 10, 2020
−Removed: Assignment and Amendment No.
−Removed: 2 of Seed Bank Supply Agreement by and among the Company, Oscine Corp., and Hadasit, dated as of January 6, 2021
−Removed: Exclusive Start-Up License Agreement by and between Cytocardia, Inc.
−Removed: (Cytocardia) and the University of Washington, acting through UW CoMotion (UW), dated as of October 9, 2018
+Added: 1 to Non-Exclusive License and Development Agreement by and between the Company and FCDI, dated as of April 12, 2021
Amendment No.
−Removed: 1 to Exclusive Start-Up License Agreement by and between Cytocardia and UW, dated as of November 6, 2019
+Added: 2 to Non-Exclusive License and Development Agreement by and between the Company and FCDI, dated as of October 26, 2021
+Added: Option and License Agreement by and between the Company and Beam Therapeutics Inc.
+Added: (Beam), dated as of October 15, 2021
Amendment No.
−Removed: 2 to Exclusive Start-Up License Agreement by and between Cytocardia and UW, dated as of July 16, 2020
−Removed: Assignment of License Agreement by and among the Company, UW, and Cytocardia, dated as of November 11, 2020
+Added: 1 to Option and License Agreement by and between the Company and Beam, dated as of June 6, 2022
Amendment No.
−Removed: 4 to Exclusive Start-Up License Agreement by and between the Company and UW, dated as of January 21, 2021
−Removed: Offer Letter and Employment Agreement by and between the Company and Sunil Agarwal, M.D., dated as of May 20, 2019
−Removed: Non-Exclusive License and Development Agreement by and between the Company and Fujifilm Cellular Dynamics, Inc., dated as of February 1, 2021
−Removed: Option and License Agreement by and between the Company and Beam Therapeutics Inc., dated as of October 15, 2021
+Added: 2 to Option and License Agreement by and between the Company and Beam, dated as of July 19, 2022
Patent License Agreement by and between the Company and the U.S.
Department of Health and Human Services, as represented by The National Cancer Institution, an institute of the National Institutes of Health, dated as of January 7, 2022
+Added: Lease Agreement by and between the Company and ARE-Seattle No.
+Added: 39, LLC, dated as of June 1, 2022
Lease Agreement by and between the Company and Pacific Commons Owner, LP, dated as of July 13, 2021
3 unchanged sentences
Certificate of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
+Added: Incorporated by Reference
+Added: Exhibit Description
Certificate of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
6 unchanged sentences
Inline XBRL Taxonomy Extension Label Linkbase Document
−Removed: Incorporated by Reference
−Removed: Exhibit Description
Inline XBRL Taxonomy Extension Presentation Linkbase Document
15 unchanged sentences
Each person whose individual signature appears below hereby authorizes and appoints Steven D.
−Removed: Harr, M.D., Nathan Hardy, and James J.
−Removed: MacDonald and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.
+Added: Harr, M.D., Nathan Hardy, and Bernard J.
+Added: Cassidy and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
30 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.